Pregnancy Related
Conditions
Keywords
Rare disease, PFIC, Pregnancy, Lactation
Brief summary
The participants of this study will be of any age who are exposed to at least 1 dose of odevixibat at any time during pregnancy (from 1 day prior to conception to pregnancy outcome) and/or at any time during lactation (up to 12 months of infant age or weaning, whichever comes first. This study will collect data obtained via a variety of sources, including enrolled pregnant or lactating participants, the healthcare providers (HCP) involved in their care or the care of their infants, if applicable, and Albireo pharmacovigilance. Study start date is either start of data collection or first patient enrolled whatever occurs earlier. The surveillance program is strictly observational; the schedule of office visits and all treatment regimens are determined by HCPs. Only data that are routinely documented in patients' medical records as part of usual care will be collected. No additional laboratory tests or HCP assessments will be required as part of this surveillance program.
Interventions
None listed
Sponsors
Ipsen
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Inclusion criteria
* Exposure to at least 1 dose of odevixibat at any time during pregnancy (from 1 day prior to conception to pregnancy outcome) and/or at any time during lactation (up to 12 months of infant age or weaning, whichever comes first). * Informed consent or IRB-/EC-approved waiver of informed consent (not applicable if reported by Albireo PV according to usual pharmacovigilance practices)
Exclusion criteria
* Refusal to provide informed consent, if required
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence rate of major congenital malformations (MCM) at birth | At birth | An abnormality of body structure or function that is present at birth; is of prenatal origin (i.e. birth defect); has significant medical, social or cosmetic consequences for the affected individual; and typically requires medical intervention. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence rate of minor congenital malformations at birth | At birth | — |
| Prevalence rate of molar or ectopic pregnancy | Throughout pregnancy, an average of 9 months | Molar pregnancy is defined as an abnormal pregnancy that happens when a sperm fertilizes an egg that does not contain any genetic material. Ectopic pregnancy is defined as a pregnancy that occurs outside of the uterine cavity, usually in one of the fallopian tubes. |
| Prevalence rate of fetal loss | Throughout pregnancy, an average of 9 months | A fetal loss that occurs for any reason at any time during pregnancy. This includes spontaneous abortion (SAB), stillbirth, elective or therapeutic abortion, fetal loss (type not specified). |
| Prevalence rate of live birth | At birth | The birth of a living fetus at ≥ 20 gestational weeks or, if gestational age is unknown, weighing ≥ 350g. |
| Prevalence rate of preterm birth | At birth | — |
| Prevalence rate of small for gestational age (SGA) | At birth | Birth weight \<10th percentile for sex and gestational age using standard growth charts for full and preterm live-born infants. |
| Prevalence rate of neonatal death | Within the first 28 days of life | — |
| Prevalence rate of infant death | Throughout the first year of life | — |
| Prevalence rate of postnatal growth deficiency | Throughout the first year of life | Weight, length or head circumference in \<10th percentile for sex and age using standard growth charts. |
| Prevalence rate of infant developmental delay | Throughout the first year of life | Failure to achieve the developmental milestones for chronological age, as defined by the Centers for Disease Control and Prevention (CDC) |
| Prevalence rate of infant hospitalization due to serious illness | Throughout the first year of life | Infant hospital visit due to a serious (i.e. results in significant disability, incapacity, or death; is life-threatening; requires inpatient or prolonged hospitalization; or is considered medically important) |
Countries
United States
Contacts
CONTACTIpsen Clinical Study Enquiries
STUDY_DIRECTORIpsen Medical Director
Ipsen
Outcome results
None listed